Franklin Resources Inc. Acquires Shares of 520,301 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

Franklin Resources Inc. bought a new position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 520,301 shares of the company’s stock, valued at approximately $7,435,000.

A number of other hedge funds have also recently added to or reduced their stakes in ARTV. Charles Schwab Investment Management Inc. bought a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth about $623,000. BNP Paribas Financial Markets acquired a new stake in Artiva Biotherapeutics during the third quarter worth about $42,000. Wellington Management Group LLP bought a new position in Artiva Biotherapeutics in the third quarter worth about $2,912,000. RA Capital Management L.P. acquired a new position in Artiva Biotherapeutics in the third quarter valued at approximately $152,234,000. Finally, Samsara BioCapital LLC bought a new position in shares of Artiva Biotherapeutics during the third quarter valued at approximately $4,506,000.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Wedbush restated an “outperform” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Friday, August 30th. Needham & Company LLC reissued a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $21.25.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ ARTV opened at $11.11 on Monday. Artiva Biotherapeutics, Inc. has a 12-month low of $9.68 and a 12-month high of $17.31. The business’s 50 day simple moving average is $11.64.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). On average, analysts predict that Artiva Biotherapeutics, Inc. will post -4.68 earnings per share for the current year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.